Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sulfonylurea · 1 trial · 1 indication
The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded.
All deaths identified during the original record study and discovered after the re-adjudication efforts began were included.
IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin.
Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.
The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as "unknown deaths," but were counted as CV deaths for the analysis of this endpoint.
The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths.
The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme \>= 2x the ULN or CK \> 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI.
The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.
Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke.
The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.
| Arm | Type | Description |
|---|---|---|
| rosiglitazone in addition to background metformin | EXPERIMENTAL | Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent. |
| rosiglitazone in addition to background sulfonylurea | EXPERIMENTAL | Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent. |
| Sulfonylurea in addition to background metformin | ACTIVE_COMPARATOR | Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. |
| Metformin in addition to background sulfonylurea | ACTIVE_COMPARATOR | Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent. |
| Name | Type | Description |
|---|---|---|
| Rosiglitazone | DRUG | Rosiglitazone maximum 8 mg per day |
| Sulfonylurea | DRUG | Sulfonylurea (SU) maximum permitted daily dose |
| Metformin | DRUG | Metformin maximum permitted daily dose . |
Inclusion Criteria: * Patients with type II diabetes mellitus as defined by 1999 World Health Organisation criteria. * Glycated haemoglobin (HbA1c) \>7.0 % to = 9.0 % at visit 1. * Use of an oral glucose lowering agent for a minimum of 6 months prior to screening and unchanged for 2 months prior to...
Sulfonylurea is a small molecule being developed by GSK plc for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 3 clinical development as an investigational drug. The drug is being studied in the metabolic therapeutic area, with a focus on managing blood glucose levels in patients with this condition.
GSK plc, traded under the ticker GSK, is the developer of Sulfonylurea. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus. GSK is responsible for the ongoing research and development of this investigational small molecule.
Sulfonylurea is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial, known as RECORD, has been completed and enrolled 4,447 participants with Type 2 Diabetes Mellitus.
Sulfonylurea has one completed Phase 3 clinical trial, identified as NCT00379769, titled 'RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes'. This trial enrolled 4,447 patients with Type 2 Diabetes Mellitus across multiple countries, including Australia, Belgium, and the United Kingdom.
Sulfonylurea is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. The completed Phase 3 trial, NCT00379769, has finished, but the drug has not yet received regulatory approval. Further development and regulatory review are required before it can be marketed.
Sulfonylurea is not the same as Rosiglitazone. The Phase 3 trial NCT00379769, titled 'RECORD', evaluated Rosiglitazone for cardiac outcomes and regulation of glycaemia in diabetes. Sulfonylurea is a separate drug being developed by GSK, and the trial data provided does not indicate that these are the same compound.